Women should not be surprised by changes the happen to their vagina, vulva and urinary tract as a resulting from the drop in the hormone, estrogen. which is a normal part of menopause and effects the vast majority of women.
However, most of us are confused, frustrated and frightened by the seemingly overnight changes to our vulvar and vaginal area. Now this is a simple, discreet solution to put an end to the pain and discomfort and allow you to regain your confidence and feminine power.
Dryness is a hallmark sign of menopause. As estrogen declines, the skin become thinner and more easily irritated, often becoming painful. Left untreated this condition known as Genitourinary Syndrome of Menopause (GSM) will continue to progress often leading to chronic urinary tract infections, urinary incontinence. and disruption to normal daily activity.
In addition to perimenopause and menopause, women who have been treated with chemotherapy, those with diabetes or circulatory issues and women who breastfeed for an extended period of time may also experience troubling vaginal symptoms regardless of their age.
A vaginal vitality serum, like GLOW Below, can help to increase hydration around your vulva, vagina and surrounding areas to soothe and improve the skin tissue quality.
It will help with soothing any irritation or discomfort, protect and repair your skin barrier, and can even help with plumping and rejuvenate saggy or thin tissues.
Most importantly, GLOW Below can be used daily as part of your regular skincare routine and will help with overall vaginal health, vaginal ph, reducing UTI’s and overall comfort
You don’t have to suffer in silence. Our
vaginal estrogen and DHEA treatment is 100% safe
and effective in treating vaginal dryness,
itching, burning, atrophy, painful sex and more.
Dr. Michelle Sands, Naturopathic Physician
As women, we put so much effort in to reverse the impact of skin aging of our face, however few stop to think how it affects our intimate area. The result is a lack of moisture, reduction in skin elasticity, and increased susceptibility to irritation, infection, and discomfort. Many women find that their relationships, physical activity and overall quality of life begin to suffer as a result.
GLOW Below was created with just a handful of the words most effective and natural ingredients to nourish your private parts with everything they need, and nothing that they do not. Unlike most products on the market, GLOW Below contains NO chemical, additives, fillers, GMO’s or preservatives. It is made with certified organic ingredients, is 100% plant based and cruelty-free. And because we believe in addressing the root cause, GLOW Below with Estrogen contains a clinically effective level of low dose bioidentical estriol and estradiol that stays local to the vagina and does not raise blood or systemic levels of estrogen. This makes it safe even for women who cannot use oral or systemic estrogen. And because the underlying cause behind all of these symptoms deficient estrogen, it works quickly and efficiently to provide long lasting relief and stronger, healthy cells and tissues. GLOW Below with DHEA contains all the same ingredients and benefits as GLOW Below with Estrogen, except in an estrogen-free formulation.
Cocoa Butter is rich in antioxidants that help fight against free radicals and reduce the signs of aging. It also contains flavonoids, which are powerful anti-inflammatory agents that can help calm irritated skin. Cocoa also contains magnesium, which helps reduce inflammation and improve blood flow.
Cocoa Butter has been used in Naturopathic Medicine to soothe sensitive tissues and the reverse atrophic vaginitis. Cocoa butter is rich with skin-loving fatty acids. It is often used to restore very dry, cracked skin and to replenish aging skin. It is deeply moisturizing, nourishing, and protective
This powerhouse ingredient provides antioxidant protection which helps protect your skin from free radicals that weaken the skin overtime and can lead to premature aging. It also aids in keeping your skin soft and supple while adding a little extra moisture to make sure everything stays moisturized and healthy. It helps repair the vaginal mucosa (the innermost layer of the vagina) and reduces dryness, itching, and burning.
Vitamin E helps tighten, firm, and moisturize the skin. This ingredient has been clinically studied to help women improve vaginal hydration and comfort.
Your skin is the first barrier of defense from the outside world. Over time, your skins natural defense barrier is exposed to external aggressors, from temperature shifts, pollution in the air, synthetic fabrics, harsh chemicals in products… the list goes on!
Add to that stress, lack of sleep, the impact of our busy lifestyles, including diet and exercise, and your skin barrier begins to break down and accelerate the aging process.
We put so much effort in to reverse the impact of skin aging of our face, however few stop to think how it affects our intimate area. The result is a lack of moisture, reduction in skin elasticity, and increased susceptibility to irritation and discomfort. Make GLOW Below your one-step skincare for down there!
Please begin using 1 pump of GLOW Below daily.
Some women will need less or more cream as time goes on. You want to use the smallest dose possible that provides relief, typically this is 1-2 pumps. After the first week, you can increase to 2 pumps if desired.
Use GLOW Below for 60 days at the recommended dose (1-2 pumps daily) We expect you will see improvements in 6-8 weeks although many of our clients experience more immediate results. After 60 days, if you have not experienced any improvements, it is safe to increase your GLOW Below dose up to 4 pumps daily, 2 in the AM and 2 in the PM. For twice a day users, we suggest pairing GLOW Below with Estrogen with GLOW Below with DHEA for best result.
After the initial 60 days of use, and once you’re experiencing improvements from daily use, you can go into a “maintenance” mode. Maintenance dosing is typically 5 times per week. You should continue at this maintenance dose. Note that if you discontinue use of the product you will return to your baseline.
You may notice a warming and/or tingling sensation at first, which should not last longer than 10 to 15 minutes. This is more common in women who have a more severe degree of irritation and it is a sign that the product is working. This sensation will subside as the tissues continue to repair.
If the warming and/or tingling sensation lasts for longer than 20 minutes, or creates a feeling of discomfort, discontinue use of GLOW Below for 72 hours. Then try using a 1 pump dose. If symptoms re-occur, consider alternating between GLOW Below and a natural moisturizer such as coconut oil or olive oil.
You can safely apply GLOW Below with your clean fingers. Apply it to your vulvar area from your clitoris, all along the labia, over the urethra and the vaginal opening to the perineum. Gently massage the serum into the labia minora and majora. This will allow the serum to get to all of the tissues that need the most nourishment. There is no need for an applicator as the ingredients in GLOW Below will make their way into the vaginal canal and the urethra as well as the entire vulvar area.
GLOW Below is PH balanced and designed for your delicate intimate area and anywhere on your body.
GLOW Below is safe externally and internally, so women with more severe dryness may wish to insert GLOW Below into the vaginal opening using a clean fingertip. Wash your hands afterward. Glow Below can also be applied by pumping onto a tissue and wiping on.
The serum will be well absorbed within 20 minutes.
GLOW Below does contain hormones so please keep out of reach of children and pets and avoid sharing hand towels.
Apply it to your vulvar area from mons pubis, over your clitoris, all along the labia, over the urethra and the vaginal opening to the perineum. Gently massage the serum into the labia minora and majora. This will allow the serum to get to all of the tissues that need the most nourishment. See diagram below to become more familiar with these terms and locations. There is no need for an applicator as the ingredients in GLOW Below will make their way into the vaginal canal and the urethra as well as the entire vulvar area.
GLOW Below is PH balanced and designed for your delicate intimate area and anywhere on your body.
Apply GLOW Below daily at any time of the day that works for you. Many women do well applying it first thing in the morning, after a shower, before or after a workout, before bed and before and after intercourse. Choose the time of day that works for you, it is safe to apply up to 4 pumps per day..
Yes, GLOW Below can be applied before intercourse, and many women using GLOW Below prior to intercourse have found it to increase their ability to achieve orgasm. It is not harmful in any way to your partner. For women concerned about using GLOW Below with Estrogen, the estrogen is full absorbed within 20 minutes and will not transfer to your partner after that time. GLOW Below with DHEA can be used immediately before intercourse, in fact, you will be pleasantly surprised by the enhances sexual sensations that GLOW Below with DHEA provides.
Note: GLOW Below contains natural emollients, so please refer to your condom packaging to determine if it has any warnings relating to the use of oil-based products
Yes. Low dose vaginal estrogen like in GLOW Below is extremely safe. There have been many studies since the WHI doing retrospective reviews for women only using low-dose vaginal estrogen products showing that there is no increased risk of cancer and cardiovascular events whatsoever. Which shows that vaginal estrogen is extremely safe. Vaginal estrogen even prevents urinary tract infections and morbidity associated with urinary tract infections, showing that it is actually more dangerous not to be using this medication in menopause. Individuals can use it safely for decades- essentially forever. You can start it when you’re 50 and take it until you’re 95 and you will only be healthier because of it.
Low-dose vaginal estrogen, what is in GLOW Below, does not actually raise blood levels of estrogen, therefore, it does not have the any risks associated with Hormone Replacement Therapy (HRT). Vaginal estrogen is a localized treatment, meaning it is only administered to the place it is aiming to treat and only have a very localized effect on the vaginal tissues themselves. This is well studied, widely documented, and supported by Cancer.org, the North American Menopause Society, and A4M. See references at the bottom of this page.
Dehydroepiandrosterone (DHEA) is a hormone that your body naturally produces in the adrenal gland. DHEA is a precursor to other hormones, including testosterone and estrogen. Vaginal DHEA can help to upregulate estrogen and provide many of the same benefits as vaginal estrogen. Is it very safe to use.
According to the research of The North American Menopause Society (NAMS): Vaginal estrogen & DHEA treatment is 100% safe and effective in treating vaginal dryness, itching, burning, atrophy, painful sex and more. See references at the bottom of this page.
GLOW Below contains only hand-picked active ingredients with no fillers or chemicals. GLOW Below is made with organic ingredients, is plant-based, paraben-free, cruelty-free, and allergen free. GLOW Below is made in the USA at a FDA registered, Kosher certified, GMP facility and is third party tested for purity.
Here is the full ingredient list for each formula:
GLOW Below with Estrogen:
Micronized Estriol USP
Micronized Estradiol USP
GLOW Below with DHEA:
UPS DHEA (Dehydroepiandroserone)
No, not at all. GLOW Below is not intended to increase serum levels of Estradiol, Estriol or DHEA. Instead the low dose of estrogen and/or DHEA is absorbed locally into the vaginal and vulvar tissues.
If you are interested in increasing your systemic levels of these hormones due to perimenopause or menopause I encourage you to check out my Healthy Hormone Club at healthyhormoneclub.com Or watch my free hormone restoration masterclass at FixHormones.com
1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. American family physician. 2000;61(10):3090–6. [PubMed] [Google Scholar]
2. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. The journal of sexual medicine. 2009;6(8):2133–42. [PubMed] [Google Scholar]
3. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.. [Climacteric : the journal of the International Menopause Society Research Support, Non-U.S. Gov’t]. 2016;19(2):188–97. [PMC free article] [PubMed] [Google Scholar]
4. Moral E, Delgado JL, Carmona F, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric : the journal of the International Menopause Society. 2018;21(2):167–73. [PubMed] [Google Scholar]
5. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas. [Consensus Development Conference Research Support, Non-U.S. Gov’t]. 2014;79(3):349–54. [PubMed] [Google Scholar]
6. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902; quiz 3–4. [PubMed] [Google Scholar]
7. DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health (Larchmt). [Comparative Study]. 2015;24(9):713–22. [PubMed] [Google Scholar]
8. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric : the journal of the International Menopause Society. [Review]. 2014;17(1):3–9. [PubMed] [Google Scholar]
9. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstetrics and gynecology. [Practice Guideline]. 2014;123(1):202–16. [PubMed] [Google Scholar]
10. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53. [PubMed] [Google Scholar]
11. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. [Practice Guideline Research Support, Non-U.S. Gov’t]. 2015;100(11):3975–4011. [PubMed] [Google Scholar]
12. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics and gynecology. [Review]. 2014;124(6):1147–56. [PMC free article] [PubMed] [Google Scholar]
13. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstetrics and gynecology. [Meta-Analysis Research Support, Non-U.S. Gov’t]. 1998;92(4 Pt 2):722–7. [PubMed] [Google Scholar]
14. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane database of systematic reviews. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]. 2016(8):CD001500. [Google Scholar]
15. Mitchell CM, Reed SD, Diem S, et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA internal medicine. 2018;178(5):681–90. [PMC free article] [PubMed] [Google Scholar]
16. Pinkerton JV, Kaunitz AM, Manson JE. Not time to abandon use of local vaginal hormone therapies. Menopause. 2018;25(8):855–8. [PubMed] [Google Scholar]
17. Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women’s EMPOWER Survey: Identifying Women’s Perceptions on Vulvar and Vaginal Atrophy and Its Treatment. The journal of sexual medicine. 2017;14(3):413–24. [PubMed] [Google Scholar]
18. Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. [Editorial]. 2014;21(9):911–6. [PubMed] [Google Scholar]
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.]. 2002;288(3):321–33. [PubMed] [Google Scholar]
20. Archer DF . Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause. [Research Support, Non-U.S. Gov’t Review]. 2010;17(1):194–203. [PubMed] [Google Scholar]
21. Vulvar Lev-Sagie A. and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. Clinical obstetrics and gynecology. [Review]. 2015;58(3):476–91. [PubMed] [Google Scholar]
22. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. American journal of obstetrics and gynecology. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2002;186(5):944–7. [PubMed] [Google Scholar]
23. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric : the journal of the International Menopause Society. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2005;8(1):83–92. [PubMed] [Google Scholar]
24. Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertility and sterility. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2010;94(6):2365–8. [PubMed] [Google Scholar]
25. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric : the journal of the International Menopause Society. [Randomized Controlled Trial]. 2010;13(3):219–27. [PubMed] [Google Scholar]
26. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. [Clinical Trial]. 2002;9(3):179–87. [PubMed] [Google Scholar]
27. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. [PMC free article] [PubMed] [Google Scholar]
28. Morch LS, Kjaer SK, Keiding N, Lokkegaard E, Lidegaard O. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study. International journal of cancer. [Research Support, Non-U.S. Gov’t]. 2016;138(6):1506–15. [PubMed] [Google Scholar]
29. Lokkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017;48(8):2266–9. [PubMed] [Google Scholar]
30. Carrasquilla GD, Frumento P, Berglund A, et al. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS medicine. [Observational Study]. 2017;14(11):e1002445. [PMC free article] [PubMed] [Google Scholar]
31. Belanger C, Speizer FE, Hennekens CH, Rosner B, Willett W, Bain C. The nurses’ health study: current findings. The American journal of nursing. [Research Support, U.S. Gov’t, P.H.S.]. 1980;80(7):1333. [PubMed] [Google Scholar]
32. Belanger CF, Hennekens CH, Rosner B, Speizer FE. The nurses’ health study. The American journal of nursing. 1978;78(6):1039–40. [PubMed] [Google Scholar]
33. Colditz GA, Manson JE, Hankinson SE. The Nurses’ Health Study: 20-year contribution to the understanding of health among women. Journal of women’s health / the official publication of the Society for the Advancement of Women’s Health Research. [Research Support, U.S. Gov’t, P.H.S.]. 1997;6(1):49–62. [Google Scholar]
34. Bao Y, Bertoia ML, Lenart EB, et al. Origin, Methods, and Evolution of the Three Nurses’ Health Studies. American journal of public health. 2016;106(9):1573–81. [PMC free article] [PubMed] [Google Scholar]
35. World Health Organization; IHD Registers: Report of the Fifth Working Group. . In: Organization WH, editor. Copenhagen; 1971. [Google Scholar]
36. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology. [Guideline Practice Guideline]. 2000;36(3):959–69. [PubMed] [Google Scholar]
37. Walker AE, Robins M, Weinfeld FD. The National Survey of Stroke. Clinical findings. Stroke. [Research Support, U.S. Gov’t, P.H.S.]. 1981;12(2 Pt 2 Suppl 1):I13–44. [PubMed] [Google Scholar]
38. Pun VC, Hart JE, Kabrhel C, Camargo CA Jr., Baccarelli AA, Laden F Prospective Study of Ambient Particulate Matter Exposure and Risk of Pulmonary Embolism in the Nurses’ Health Study Cohort. Environmental health perspectives. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2015;123(12):1265–70. [PMC free article] [PubMed] [Google Scholar]
39. Kabrhel C, Varraso R, Goldhaber SZ, Rimm E, Camargo CA, Jr. Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ. [Research Support, N.I.H., Extramural]. 2011;343:d3867. [PMC free article] [PubMed] [Google Scholar]
40. Poole EM, Lin WT, Kvaskoff M, De Vivo I, Terry KL, Missmer SA. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer causes & control : CCC. 2017;28(5):437–45. [PMC free article] [PubMed] [Google Scholar]
41. Puckett CD. The Educational Annotation of ICD-9-CM; Diseases and Procedures Tabular Lists. Reno, NV; 1986. [Google Scholar]
42. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. American journal of epidemiology. [Research Support, U.S. Gov’t, P.H.S.]. 1994;140(11):1016–9. [PubMed] [Google Scholar]
43. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. American journal of epidemiology. [Research Support, U.S. Gov’t, P.H.S.]. 1984;119(5):837–9. [PubMed] [Google Scholar]
44. Zahl PH, Jorgensen KJ, Maehlen J, Gotzsche PC. Biases in estimates of overdetection due to mammography screening. The Lancet Oncology. [Comment Letter]. 2008;9(3):199–201; author reply −2. [PubMed] [Google Scholar]
45. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. Jama. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Intramural]. 2013;310(13):1353–68. [PMC free article] [PubMed] [Google Scholar]
46. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstetrics and gynecology. [Research Support, Non-U.S. Gov’t]. 2006;108(6):1354–60. [PubMed] [Google Scholar]
47. Pinkerton JV, Kaunitz AM, Manson JE. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. Menopause. 2017;24(12):1329–32. [PubMed] [Google Scholar]
48. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2009;16(1):30–6. [PubMed] [Google Scholar]
49. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. The Cochrane database of systematic reviews. [Meta-Analysis Review] 2006(4):CD001500. [PubMed] [Google Scholar]
50. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Use of low potency estrogens does not reduce the risk of hip fracture. Bone. [Research Support, Non-U.S. Gov’t]. 2002;30(4):613–8. [PubMed] [Google Scholar]
51. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. American journal of obstetrics and gynecology. [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 1997;177(1):115–9. [PubMed] [Google Scholar]